Abbott (NYSE:ABT) today announced new clinical data highlighting the importance of managing diabetic ketoacidosis (DKA).
1d
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
Abbott (NYSE: ABT), the global healthcare leader, announced new data revealing diabetic ketoacidosis (DKA) remains an important, yet often undetected health concern for people living with both Type 1 ...
NEW ORLEANS -- Patients with type 2 diabetes (T2D) hospitalized for ketoacidosis had a higher mortality rate versus patients with type 1 diabetes (T1D), according to a study of national data. In the ...
NORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (NASDAQ: MMED), a global leader in diabetes technology, today announced an expanded agreement with Abbott to collaborate on commercializing ...
Diabetic ketoacidosis (DKA) is a complication of diabetes. It can occur when the body does not have enough insulin to use sugar as energy. Instead, it breaks down fat and produces ketones. This can ...
LAS VEGAS — Off-label use of GLP-1 drugs by people with type 1 diabetes (T1D) did not lead to diabetic ketoacidosis (DKA) or pancreatitis in a large 1-year single-center study. Moreover, GLP-1 agonist ...
The world's first dual continuous glucose and ketone monitor is designed to help prevent diabetic ketoacidosis (DKA).
GlobalData on MSN
Abbott obtains CE mark for duo of glucose-ketone monitors
The Libre Duo systems are the first glucose-ketone monitors to reach the diabetes market.
Monitoring blood sugar and ketone levels can help prevent complications. In some cases, people may experience euglycemic diabetic ketoacidosis. This refers to when a person has high ketone levels but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results